Form 4: Biocryst Pharmaceuticals Director Acquires Stock

Biocryst Pharmaceuticals Director Vincent Milano acquired 1,122 shares of common stock for $8.91 per share, as reported in a Form 4 filing.

Summary

• Vincent Milano, a Director at Biocryst Pharmaceuticals Inc. (BCRX), acquired 1,122 shares of common stock on May 29, 2026.
• The acquisition was made in lieu of 50% of the quarterly Board Chair retainer, which amounts to $20,000.
• The shares were acquired at a price of $8.91 per share.
• Following this transaction, Milano beneficially owns 93,189 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a director acquiring stock as part of compensation, which can signal confidence, but it is not a large open market purchase.

Positives

• Director acquisition of company stock can signal confidence in the company's future prospects.
• The transaction represents a portion of the director's compensation, indicating ongoing engagement and commitment.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it is a statement of changes in beneficial ownership.

Industry Context

StockSavvy.ai notes that insider stock purchases, particularly by directors, are often viewed positively by the market as they can indicate a belief in the company's intrinsic value and future growth potential within the biopharmaceutical sector.

Stakeholder Impact

• Shareholders may view the director's acquisition of stock positively, interpreting it as a sign of confidence in the company's future performance.

Key Dates

Keywords

Biocryst Pharmaceuticals, BCRX, Form 4, Insider Trading, Director Compensation, Stock Acquisition, Beneficial Ownership